Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALGeneric

VANCENASE AQ

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

Standard Dose
EQ 0.042MG DIPROP/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VANCENASE AQ is listed in Drugs@FDA under application 019589 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BECLOMETHASONE DIPROPIONATE MONOHYDRATE Form and strength SPRAY, METERED;NASAL - EQ 0.042MG DIPROP/SPRAY Sponsor SCHERING Submission history Latest submission status date: 2000-08-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview VANCENASE AQ is listed in Drugs@FDA under application 019589 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BECLOMETHASONE DIPROPIONATE MONOHYDRATE Form and strength SPRAY, METERED;NASAL - EQ 0.042MG DIPROP/SPRAY Sponsor SCHERING Submission history Latest submission status date: 2000-08-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
VANCENASE AQ (BECLOMETHASONE DIPROPIONATE MONOHYDRATE) | Drug Monograph | MedicHelpline